

Gateway Health Prior Authorization Criteria Buprenorphine Sublingual Tablets

All requests for Buprenorphine Sublingual Tablets require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Buprenorphine Sublingual Tablets Prior Authorization Criteria:

Coverage may be provided with a <u>diagnosis</u> of Opioid Use Disorder and the following criteria is met:

- The member is 16 years of age or older
- The member is pregnant, breast feeding, or is undergoing induction therapy with the intent to covert to Suboxone Film in 4 weeks or less
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- If the member is taking buprenorphine in combination with a benzodiazepine or CNS depressant, documentation of **ONE** of the following must be submitted:
 - A tapering plan for the benzodiazepine or CNS depressant AND provider attestation the member has been educated about the serious risks of combined use, including overdose and death, that can occur with CNS depressants even when used as prescribed, as well as when used illicitly (if applicable)
 - Attestation of a urine or blood drug screening within the last 3 months AND attestation the provider has verified the member is receiving prescribed benzodiazepines or other CNS depressants for anxiety or insomnia, concomitant use with these agents is medically necessary, and alternative treatment options for these conditions were tried and failed, contraindicated, or inappropriate
- Documentation the prescriber or the prescribing provider's delegate has conducted a search of the Pennsylvania Prescription Drug Monitoring Program (PDMP) for the recipient's controlled substance prescription history before prescribing buprenorphine treatment.
- **Initial Duration of Approval:** 6 months
- Reauthorization criteria:
 - Buprenorphine SL tablets is considered medically necessary and will be reauthorized for treatment of opioid use disorder through the dispensing pharmacy when the following criteria is met:
 - The provider attests the member is still pregnant or breast feeding.
- Reauthorization Duration of Approval: 6 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



BUPRENORPHINE SUBLINGUAL TABLETS

PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. FAX: (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative.

PHON	NE: (800) 392-114/ Monda		_	am to 5:00pm					
	PROVIDER I	<u>NFORMATIO</u>	ON						
Requesting Provider:			NPI:						
Provider Specialty:				Office Contact:					
Office Address:				Office Phone:					
			Office I	Fax:					
MEMBER INFORMATION									
Member Name:		DOB:							
Gateway ID:		Member weig	ht:	pounds or	kg				
	REQUESTED DRI			-					
Medication:	REQUESTED DI	Strengt							
Frequency:		Duratio							
Is the member currently receiving r	requested medication? V			e Medication Initiated:					
is the member currently receiving r			Dat	e Medication Initiated.					
mi: 1: .: '11.1 1.11 1 □		nformation							
	at a pharmacy OR	• •	ICODE						
	medically (if medically ple								
Place of Service: Hospital		mber's home [r					
	Place of Servi								
Name:			NPI:						
Address:			Phone:						
	MEDICAL HISTORY (C	7I-4- f	ATT	vinosta)					
	MIDDICAL INSTURI (C	complete for A	ALL rec	uests)					
		_	ALL rec	[uests]					
Diagnosis:	ICD-10 Cod	de:			in 4 weeks				
Diagnosis: Is the member pregnant, breast feed	ICD-10 Cod	de:			in 4 weeks				
Diagnosis:	ICD-10 Cod	de:			in 4 weeks				
Diagnosis: Is the member pregnant, breast feed or less? Yes No	ICD-10 Coo	de:on therapy with	h the int	ent to covert to Suboxone Film	in 4 weeks				
Diagnosis: Is the member pregnant, breast feed	ICD-10 Coo	de:on therapy with	h the int		in 4 weeks				
Diagnosis:	ICD-10 Cooding, or undergoing induction	de:on therapy with	h the int	ent to covert to Suboxone Film	in 4 weeks				
Diagnosis: Is the member pregnant, breast feed or less? Yes No	ICD-10 Cooding, or undergoing induction	de:on therapy with	h the int	ent to covert to Suboxone Film	in 4 weeks				
Diagnosis:	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deprooxes:	on therapy with	h the int	ent to covert to Suboxone Film					
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a large or less, please check the applicable large.	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS depoxes: about the serious risks of c	on therapy with	h the int	ent to covert to Suboxone Film No g overdose and death, that can o					
Diagnosis: Is the member pregnant, breast feed or less? ☐ Yes ☐ No Is the member concurrent taking a last the member concurrent taking a last the member check the applicable last the member has been educated CNS depressants even when us	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as	on therapy with pressant? \(\sum_{\text{Y}} \)	h the int	ent to covert to Suboxone Film No g overdose and death, that can oapplicable)					
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member check the applicable last the member has been educated CNS depressants even when us A tapering plan for discontinuation.	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as tion of the benzodiazepine of	on therapy with pressant? \(\sum_{Y} \) combined use, in when used illipor CNS depres	h the int Yes includin icitly (if sant is p	no No g overdose and death, that can o applicable) rovided	occur with				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last tapering plan for discontinuat The member is receiving benzoon	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as tion of the benzodiazepine of diazepines or other CNS de	on therapy with pressant? \(\sum \) You combined use, it when used illied or CNS depress appressants for a	h the int	no No g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi	occur with				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member concurrent taking a last the member has been educated CNS depressants even when us A tapering plan for discontinuat The member is receiving benzoon agents is medically necessary, a	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we	on therapy with pressant? \(\sum \) combined use, in when used illustrated and farere tried and farere tri	h the int	no No g overdose and death, that can o applicable) rovided	occur with				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last tapering plan for discontinuat The member is receiving benzoon	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we	on therapy with pressant? \(\sum \) combined use, in when used illustrated and farere tried and farere tri	h the int	no No g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi	occur with				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last tapering plan for discontinuated agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary.	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a scion of the benzodiazepine of diazepines or other CNS depand alternative treatment we thin the past 3 months is prescribed.	on therapy with pressant? \(\subseteq \text{Y} \) combined use, it when used illipor CNS depress appressants for a greet tried and factorided	h the int Yes includin icitly (if sant is p anxiety of	no g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi nappropriate (document in secti	occur with th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member concurrent taking a last the member has been educated CNS depressants even when us A tapering plan for discontinuat The member is receiving benzoon agents is medically necessary, a	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a scion of the benzodiazepine of diazepines or other CNS depand alternative treatment we thin the past 3 months is prescribed.	on therapy with pressant? \(\subseteq \text{Y} \) combined use, it when used illipor CNS depress appressants for a greet tried and factorided	h the int Yes includin icitly (if sant is p anxiety of	no g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi nappropriate (document in secti	occur with				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last tapering plan for discontinuated agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary.	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD)	on therapy with pressant? \(\subseteq \) combined use, is when used illipor CNS depress appressants for a greater tried and factorided OMP) prescripts	h the int	no g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi nappropriate (document in secti	occur with th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a late of the second service of less? Yes No Is the member concurrent taking a late of the second service of the second second service of the second secon	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD CURRENT or PR)	on therapy with pressant? \(\subseteq \text{Y} \) combined use, in the when used illipor CNS depresses and the pressants for a greater tried and factorided (a) combined use, in the pressent of the pressant of the pressa	h the interest of the control of the	no g overdose and death, that can of applicable) rovided or insomnia, concomitant use with nappropriate (document in section or provided or insomnia).	th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last tapering plan for discontinuated agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering or blood drug screen with the member is receiving benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary, a last tapering benzoon agents is medically necessary.	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD)	on therapy with pressant? \(\subseteq \) combined use, is when used illipor CNS depress appressants for a greater tried and factorided OMP) prescripts	h the interest of the control of the	no g overdose and death, that can o applicable) rovided or insomnia, concomitant use wi nappropriate (document in secti	th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member has been educated CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian Drugelian CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian CNS depressants even when us Prescription Drugelian CNS depressants even Prescription Drugelian CNS d	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD CURRENT or PR)	on therapy with pressant? \(\subseteq \text{Y} \) combined use, in the when used illipor CNS depresses and the pressants for a greater tried and factorided (a) combined use, in the pressent of the pressant of the pressa	h the interest of the control of the	no g overdose and death, that can of applicable) rovided or insomnia, concomitant use with nappropriate (document in section or provided or insomnia).	th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member has been educated CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian Drugelian CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian CNS depressants even when us Prescription Drugelian CNS depressants even Prescription Drugelian CNS d	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD CURRENT or PR)	on therapy with pressant? \(\subseteq \text{Y} \) combined use, in the when used illipor CNS depresses and the pressants for a greater tried and factorided (a) combined use, in the pressent of the pressant of the pressa	h the interest of the control of the	no g overdose and death, that can of applicable) rovided or insomnia, concomitant use with nappropriate (document in section or provided or insomnia).	th these ion below)				
Is the member pregnant, breast feed or less? Yes No Is the member concurrent taking a last the member concurrent taking a last the member has been educated CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian Drugelian CNS depressants even when us A tapering plan for discontinuat The member is receiving benzon agents is medically necessary, a last the member's Prescription Drugelian CNS depressants even when us Prescription Drugelian CNS depressants even Prescription Drugelian CNS d	ICD-10 Cooding, or undergoing induction benzodiazepine or CNS deproxes: about the serious risks of ced as prescribed, as well as a sion of the benzodiazepine of diazepines or other CNS depend alternative treatment we thin the past 3 months is program (PD CURRENT or PR)	on therapy with pressant? \(\subseteq \text{Y} \) combined use, in the when used illipor CNS depresses and the pressants for a greater tried and factorided (a) combined use, in the pressent of the pressant of the pressa	h the interest of the control of the	no g overdose and death, that can of applicable) rovided or insomnia, concomitant use with nappropriate (document in section or provided or insomnia).	th these ion below)				



BUPRENORPHINE SUBLINGUAL TABLETS

PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. FAX: (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative.

PHONE : (800) 392-1147 Monday through Friday 8:30am to 5:00pm									
MEMBER INFORMATION									
Member Name:	DOB:								
Gateway ID:	Member weight	:	pounds or	_kg					
REAUTHORIZATION									
Is the member currently pregnant or breastfeeding?									
SUPPORTING INFORMATION or CLINICAL RATIONALE									
Prescribing Provider Signature		Da	te						